Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

Novartis day

More data backs Novartis’ serelaxin in heart failure

European Society of Cardiology (ESC) meeting told of significant additional benefits

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

- PMLiVE

Novartis takes breast cancer campaign to Pinterest

Expands ongoing digital awareness efforts for advanced breast cancer

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

Novartis building

Novartis said to want out of Indian vaccines venture

Reports in India claim the pharma company is pulling out of its deal with Panacea Biotec

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

Takeda expands Latin American footprint

Opens new subsidiary in Peru

- PMLiVE

Phase III data raise hopes for Takeda’s vedolizumab

Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links